Quality of care for secondary cardiovascular disease prevention in 2009–2017: population-wide cohort study of antiplatelet therapy use in Scotland
<p><strong>Background:</strong> Antiplatelet therapy (APT) can substantially reduce the risk of further vascular events in individuals with established atherosclerotic cardiovascular disease (ASCVD). However, knowledge regarding the extent and determinants of APT use is li...
Κύριοι συγγραφείς: | Thalmann, I, Preiss, D, Schlackow, I, Gray, A, Mihaylova, B |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
BMJ Publishing Group
2023
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Antiplatelet therapy use for the secondary prevention of cardiovascular disease in 2009-2017: a population-wide retrospective cohort study of Scotland
ανά: Thalmann, I, κ.ά.
Έκδοση: (2022) -
Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009–2017
ανά: Thalmann, I, κ.ά.
Έκδοση: (2022) -
Cholesterol- and blood pressure-lowering drug use for secondary cardiovascular prevention in 2004 - 2013 Europe
ανά: Achelrod, D, κ.ά.
Έκδοση: (2016) -
Determinants of medication use for the secondary prevention of cardiovascular disease
ανά: Thalmann, I
Έκδοση: (2021) -
Antiplatelets in secondary stroke prevention
ανά: Olga eShulga, κ.ά.
Έκδοση: (2011-07-01)